Phase 3 CONDOR Study of PYL: The Potential To Improve The Outcome of Recurrent Prostate Cancer

490 words 8% vs 1306 words 3% According to a recent Globe Newswire release, Progenics Pharmaceuticals, an oncology company that specializes in artificial intelligence and targeted therapies, announced results for its Phase…

Continue Reading Phase 3 CONDOR Study of PYL: The Potential To Improve The Outcome of Recurrent Prostate Cancer
New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups
truthseeker08 / Pixabay

New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups

According to a story from journals.lww.com, The Lazarex Cancer Foundation and the University of California San Francisco have announced plans to work together on a three year study that will…

Continue Reading New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups
A Recent Discovery Could Make Cancer Treatments More Effective
ColiN00B / Pixabay

A Recent Discovery Could Make Cancer Treatments More Effective

According to a story from news-medical.net, scientists may have made a significant breakthrough discovery that could make cancer treatment more effective. The discovery involves a new method that breaks through…

Continue Reading A Recent Discovery Could Make Cancer Treatments More Effective

FDA Begins Priority Review of Xtandi, a Drug Candidate for Metastatic Hormone-Sensitive Prostate Cancer

According to a press release from American pharmaceutical giant Pfizer, Inc. the FDA recently agreed to review a supplemental New Drug Application for Xtandi. Xtandi was first approved for the…

Continue Reading FDA Begins Priority Review of Xtandi, a Drug Candidate for Metastatic Hormone-Sensitive Prostate Cancer
ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
source: pixabay.com

ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

Since the 1940s oncologists have been focusing on tumors at the location in the body where the tumors originated. According to a recent FDA press release, this is the third…

Continue Reading ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
Large Scale Trial Aims to Test Precision Medicines Based on Genomic Profiling in a Variety of Cancers
source: pixabay.com

Large Scale Trial Aims to Test Precision Medicines Based on Genomic Profiling in a Variety of Cancers

According to a story from Newswise, Quest Diagnostics, a laboratory that specializes in diagnostic information, has announced plans to participate in a unique, large scale trial called NCI-MATCH, which stands…

Continue Reading Large Scale Trial Aims to Test Precision Medicines Based on Genomic Profiling in a Variety of Cancers

A Brief Discussion of How Cell and Gene Therapies are Being Improved for Future Generations

  While the last few years have seen major advances in all areas of the pharmaceutical industry, some of the newest and brightest talents are now focusing on cell and…

Continue Reading A Brief Discussion of How Cell and Gene Therapies are Being Improved for Future Generations

Research Team Identifies Diagnostic Errors in Three Classes of Disease Associated with a High Death Rate or Permanent Disability

  The number of people in the U.S. who are permanently disabled or who die each year as a result of misdiagnosis is estimated to be over 100,000. EurekAlert recently reported…

Continue Reading Research Team Identifies Diagnostic Errors in Three Classes of Disease Associated with a High Death Rate or Permanent Disability